AstraZeneca has initiated the worldwide withdrawal of its COVID-19 vaccine due to a surplus of available updated vaccines since the pandemic.
The company also said it would proceed to withdraw the vaccine Vaxzevria’s marketing authorisations within Europe, according to Reuters.
“As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.
The brand provided the first consignment of COVID-19 vaccines to Nigeria and many African countries at the peak of the pandemic in 2021.
According to reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.
The firm’s application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.
London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.
